The SABCS 2024 (San Antonio Breast Cancer Symposium) is taking place from December 10th to 13th, 2024 at the Henry B. Gonzalez Convention Center in San Antonio, TX, USA.
SABCS is expected to attract around 10,000+ attendees from more than 102 countries, including oncologists, researchers, and healthcare professionals.
This Symposium is designed to provide state-of-the-art information on the experimental biology, etiology, prevention, diagnosis, and therapy of breast cancerand premalignant breast disease to an international audience of academic and private physicians and researchers.
This international event primarily targets academic and private physicians, as well as researchers in medical, surgical, gynecologic, and radiation oncology, along with patient advocates and other relevant healthcare professionals.
Healthcare Professionals and Organizations shared about this Conference on Social Media:
“Sarah McLaughlin, Yvonne Florance, Stephanie Wong, and Atif Khan discussed ‘Optimizing Local Therapy’ in an SABCS24 educational session moderated by Tari King.”
“Day 2 Highlights Community Oncology:
1. EMBER3: Oral SERD in HR+
2. OlympiA: PARPi in gBRCA
3. Surgery in gBRCA
EMBER3: Ph III, Imlunestrant +/- Abemaciclib in HR+ advanced BC – Komal Jhaveri
– Imlunestrant alone for mESR1(mPFS: 5.5mos vs 3.8mos)
– Combo mPFS with all comers (9.4mos vs 5.5mos), regardless of CDK4/6 exposure
– If co-PIK3CA, Capi or this combo?
OlympiA: Update, Ph III, Olaparib in mBRCA HER2 -ve, EBC, high-risk s/p local Rx + neo or adj chemo, at 6yrs:
– iDFS by 9.4% & DDFS by 7.8%
– mOS by 4.4% (87.5% vs 83.2%), HR: 0.72
– Remains the current SoC in this patient population
Risk Reduction surgery in young BRCA carriers: <40 years old with Stage I-III breast cancer undergoing Risk-reducing mastectomy (RRM) and salpingo-oophorectomy (RRSO)
– RRM and/or RRSO associated with/ better OS
– RRSO benefit more pronounced with BRCA1.”
“Impressive results from a randomized trial of neoadjuvant SHR-A1811 x8 (aka T-DXd cousin) +/- pyrotinib vs TCHP for mostly stage III HER2+ eBC. Comparable pCR rates across arms. Bodes well for DB11, though key differences in the dose and trial design may have relevant impact.”
“It was a pleasure to watch AACR Board Member Christina Curtis deliver her AACR Outstanding Breast Cancer Investigator Award lecture. We thank BCRF Cure for supporting this award, which honors Christina for advancing our knowledge of the molecular determinants of breast cancer.”
“Great panel on case based discussion on ER positive breast cancer! Daniel Stover presenting data on ctDNA and clinical utility in MBC!”
“Helpful summary on partial breast irradiation by Dr. Atif Khan including his thoughts on PBI now that we’re considering SLNB omission.”
“‘EMBER-3 Trial Results’
Imlunestrant improved PFS in HR+/HER2- mBC with ESR1 mutations: 5.5 vs 3.8 months(vs standard endocrine therapy).
Adding abemaciclib boosted PFS in all patients: 9.4 vs 5.5 months (43% low progression/death).
Fewer risks of bradycardia, high cholesterol, and visual issues vs other SERDs.”
“What to do here? Current SOC is endocrine therapy + CDK4/6 inhibitor but SONIA showed that endocrine therapy alone may be just as good, adding a CDK4/6i later with progression – and preserves QOL better, including lessening financial toxicity.”
“Educational Session 8: Optimizing
Local Therapy
Topic 2: Axillary Management: When to Dissect and When to Radiate by Stephanie Wong.”
“Great panel discussion regarding importance of communication with patients during treatment planning. To make the best decisions we need to educate patients, empowering them to make informed decisions, says Amy Beumer. So much to consider!”
“Outstanding educational session lead by Paolo Tarantino about Antibody Drug conjugates analyzing all the cone of possibilities in the future.”
“Outstanding session on optimizing local regional therapy in breast cancer led by Tari King.
We’re making great progress in “rightsizing” surgery and radiation.”
“My first takeaway from SABCS24. The EMBER3 of new oral SERD imlunestrant vs fulvestrant or exemestane vs imlune+abemaciclib in HR+/HER2neg MBC. This study showed in II-line scenario that imlunestrant is superior to ET alone in ESR1mutant patients. AKA welcome to elacestrant 2.”
“My amazing super star mentee Mariya Rozenblit with the most amazing advocate Kelly Shanahan in SABCS24.”
“Dr. Sarah McLaughlin nicely summarizes lymphedema surgical prevention and management strategies. There is a significant need but data are mixed especially for prevention. Like many I eagerly await the Alliance ARM trial results.”
“EMBER-3
Imulen+ abema vs Imlun vs SOC ET
Imlun superior to SOC ET in ESR1m, not in ITT
Imlun + abema vs Imlun, PFS 9.4 vs 5.5 mo, HR 0.57, p<0.0001 (better in ESR1m + without ESR1m)
(65% prior cdk4/6i)”
“Thank you Dr. Roberto Salgado for the masterclass on TILs at SABCS.
Key takeaway:
“TILs are for TNBC (and HER2) what grade is for luminal disease.”
“Truly excellent talk from Dr. Stephanie Wong on contemporary axillary management – we’ve come a long way, axillary recurrence is a rare event, thoughtful multidisciplinary management and future trials will guide the current controversies.”
“What about ADCs in ER+ disease? HER2 expression is important because even rise with HER2 ultra low derived benefit.
And while PFS with TDXd was better, there were 3 deaths due to ILD.”
“Exploring the power of genomic insights from a single core biopsy sample! Uncovering crucial information for personalized medicine and improving patient outcomes.”
“Rockstar patient advocate, super proud of Amy, who knocked it out of the park SABCS Education Session 6: Case Based Clinical Approach to ER+ MBC. Congratulate her, you’ll have to get in line!”
“Best part of SABCS24? Having lunch with our amazing Herbert Irving Comprehensive Cancer Center, Columbia Medicine dream team!”
“Great presentation by Dr Maria Karsten from Germany presenting results of the ProB study + discussion by Gabrielle Rocque. We have enough evidence that remote symptom monitoring is useful for patients. Why are we still not using it widely?”
“Future Directions in Antibody Drug Conjugates: John Lambert, Giuseppe Curigliano, Ingrid Mayer, and Paolo Tarantino addressed this topic in the SABCS24 People’s Choice Educational Session.”
Highlights from Day 1 of SABCS 2024